SEQUENT Stock Overview
Operates in the veterinary healthcare business in Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sequent Scientific Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹198.18 |
| 52 Week High | ₹240.70 |
| 52 Week Low | ₹92.05 |
| Beta | 0.82 |
| 11 Month Change | 19.99% |
| 3 Month Change | 23.99% |
| 1 Year Change | 60.53% |
| 33 Year Change | 29.61% |
| 5 Year Change | 186.80% |
| Change since IPO | 10.47% |
Recent News & Updates
Recent updates
We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt
Sep 27
What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You
Sep 05Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)
Apr 05Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet
Mar 10Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?
Jan 31How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?
Jan 17Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?
Jan 05What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?
Dec 24Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?
Dec 12
Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly
Nov 22Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)
Nov 10The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It
Oct 20How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?
Oct 05Shareholder Returns
| SEQUENT | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.6% | 1.1% | 2.0% |
| 1Y | 60.5% | 43.3% | 28.6% |
Return vs Industry: SEQUENT exceeded the Indian Pharmaceuticals industry which returned 43.3% over the past year.
Return vs Market: SEQUENT exceeded the Indian Market which returned 28.6% over the past year.
Price Volatility
| SEQUENT volatility | |
|---|---|
| SEQUENT Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: SEQUENT's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: SEQUENT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 1,195 | Rajaram Narayanan | www.sequent.in |
Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products.
Sequent Scientific Limited Fundamentals Summary
| SEQUENT fundamental statistics | |
|---|---|
| Market cap | ₹49.45b |
| Earnings (TTM) | ₹164.81m |
| Revenue (TTM) | ₹14.49b |
300.0x
P/E Ratio3.4x
P/S RatioIs SEQUENT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEQUENT income statement (TTM) | |
|---|---|
| Revenue | ₹14.49b |
| Cost of Revenue | ₹8.10b |
| Gross Profit | ₹6.39b |
| Other Expenses | ₹6.23b |
| Earnings | ₹164.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 44.10% |
| Net Profit Margin | 1.14% |
| Debt/Equity Ratio | 60.9% |
How did SEQUENT perform over the long term?
See historical performance and comparison